A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]

Wendy E. Huang; Christine Archer; Desmond Yip; Yada Kanjanapan; Geoffrey  Peters

doi:10.1111/ajco.13263

Abstract

Background: Nivolumab, a human IgG4 monoclonal antibody against programmed death 1 (PD-1), is approved for metastatic melanoma. The CheckMate 238 trial demonstrated one year of adjuvant nivolumab, compared with ipilimumab in resected Stage III and IV melanoma, provided longer recurrence-free survival (RFS) and lower incidence of immune related adverse events (irAEs). Patients with resected stage III and IV melanoma received adjuvant nivolumab via a patient access program (PAP) from August 2018 at our institution. This study examined local data regarding RFS and irAEs in this cohort.

Original language	English
Pages (from-to)	173-174
Journal	Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019
Volume	15
Issue number	0
DOIs	https://doi.org/10.1111/ajco.13263
Publication status	Published - 2019
Event	2019 COSA 46th Annual Scientific Meeting: Urological cancer; Age and gender in cancer practice; Digital health in cancer - Adelaide Convention Centre, South Australia Duration: 1 Jan 2019 → … https://onlinelibrary.wiley.com/toc/17437563/2019/15/S9

Access to Document

10.1111/ajco.13263

Cite this

Huang, W. E., Archer, C., Yip, D., Kanjanapan, Y., & Peters, G. (2019). A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]. Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019, 15(0), 173-174. https://doi.org/10.1111/ajco.13263

Huang, Wendy E. ; Archer, Christine ; Yip, Desmond et al. / A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]. In: Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019. 2019 ; Vol. 15, No. 0. pp. 173-174.

@article{2bd3cf21ba294bb68f2f23cb7d402c6c,

title = "A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]",

abstract = "Background: Nivolumab, a human IgG4 monoclonal antibody against programmed death 1 (PD-1), is approved for metastatic melanoma. The CheckMate 238 trial demonstrated one year of adjuvant nivolumab, compared with ipilimumab in resected Stage III and IV melanoma, provided longer recurrence-free survival (RFS) and lower incidence of immune related adverse events (irAEs). Patients with resected stage III and IV melanoma received adjuvant nivolumab via a patient access program (PAP) from August 2018 at our institution. This study examined local data regarding RFS and irAEs in this cohort.",

author = "Huang, {Wendy E.} and Christine Archer and Desmond Yip and Yada Kanjanapan and Geoffrey Peters",

year = "2019",

doi = "10.1111/ajco.13263",

language = "English",

volume = "15",

pages = "173--174",

journal = "Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019",

issn = "1743-7555",

publisher = "Central Board of Irrigation and Power",

number = "0",

note = "2019 COSA 46th Annual Scientific Meeting: Urological cancer; Age and gender in cancer practice; Digital health in cancer ; Conference date: 01-01-2019",

url = "https://onlinelibrary.wiley.com/toc/17437563/2019/15/S9",

}

Huang, WE, Archer, C, Yip, D, Kanjanapan, Y & Peters, G 2019, 'A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]', Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019, vol. 15, no. 0, pp. 173-174. https://doi.org/10.1111/ajco.13263

A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]. / Huang, Wendy E.; Archer, Christine; Yip, Desmond et al.
In: Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019, Vol. 15, No. 0, 2019, p. 173-174.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]

AU - Huang, Wendy E.

AU - Archer, Christine

AU - Yip, Desmond

AU - Kanjanapan, Yada

AU - Peters, Geoffrey

PY - 2019

Y1 - 2019

N2 - Background: Nivolumab, a human IgG4 monoclonal antibody against programmed death 1 (PD-1), is approved for metastatic melanoma. The CheckMate 238 trial demonstrated one year of adjuvant nivolumab, compared with ipilimumab in resected Stage III and IV melanoma, provided longer recurrence-free survival (RFS) and lower incidence of immune related adverse events (irAEs). Patients with resected stage III and IV melanoma received adjuvant nivolumab via a patient access program (PAP) from August 2018 at our institution. This study examined local data regarding RFS and irAEs in this cohort.

AB - Background: Nivolumab, a human IgG4 monoclonal antibody against programmed death 1 (PD-1), is approved for metastatic melanoma. The CheckMate 238 trial demonstrated one year of adjuvant nivolumab, compared with ipilimumab in resected Stage III and IV melanoma, provided longer recurrence-free survival (RFS) and lower incidence of immune related adverse events (irAEs). Patients with resected stage III and IV melanoma received adjuvant nivolumab via a patient access program (PAP) from August 2018 at our institution. This study examined local data regarding RFS and irAEs in this cohort.

U2 - 10.1111/ajco.13263

DO - 10.1111/ajco.13263

M3 - Meeting Abstract

SN - 1743-7555

VL - 15

SP - 173

EP - 174

JO - Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019

JF - Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019

IS - 0

T2 - 2019 COSA 46th Annual Scientific Meeting: Urological cancer; Age and gender in cancer practice; Digital health in cancer

Y2 - 1 January 2019

ER -

Huang WE, Archer C, Yip D, Kanjanapan Y, Peters G. A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]. Asia-Pacific Journal of Clinical Oncology Volume 15, Issue S9 Special Issue: COSA's 44th Annual Scientific Meeting, Urological Cancer; Age and Gender in Cancer 2019. 2019;15(0):173-174. doi: 10.1111/ajco.13263

A Real World Study on Adjuvant Nivolumab: Recurrence Free Survival and Toxicity in Resected Stage III and IV Melanoma [Meeting Abstract]

Abstract

Access to Document

Fingerprint

Cite this